Sodium-glucose cotransporter inhibitors: beyond glycaemic control

Diabetes increases the risk of adverse cardiovascular and renal events. Recently, sodium–glucose co-transporter 2 (SGLT2) inhibitors have been demonstrated to reduce cardiovascular complications and slow diabetic kidney disease progression in patients with type 2 diabetes. The glycaemic control exer...

Descripción completa

Detalles Bibliográficos
Autores principales: Vergara, Ander, Jacobs-Cachá, Conxita, Soler, María José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Sglt2 Inhibitors
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543973/
https://www.ncbi.nlm.nih.gov/pubmed/31198226
http://dx.doi.org/10.1093/ckj/sfz019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543973/
https://www.ncbi.nlm.nih.gov/pubmed/31198226
http://dx.doi.org/10.1093/ckj/sfz019

Ejemplares similares